Teva Pharmaceutical Industries (NYSE:TEVA) Lowered to “Hold” Rating by StockNews.com

StockNews.com downgraded shares of Teva Pharmaceutical Industries (NYSE:TEVA) from a buy rating to a hold rating in a report released on Thursday morning.

Other equities research analysts have also recently issued reports about the stock. Bank of America decreased their price target on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday, March 6th. Piper Sandler boosted their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a report on Friday, January 17th. UBS Group decreased their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a report on Thursday, January 30th. Finally, Barclays dropped their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and an average price target of $23.43.

Teva Pharmaceutical Industries Trading Down 1.1 %

Shares of Teva Pharmaceutical Industries stock opened at $15.52 on Thursday. The company’s fifty day moving average is $17.35 and its two-hundred day moving average is $18.14. Teva Pharmaceutical Industries has a 1 year low of $12.51 and a 1 year high of $22.80. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The company has a market capitalization of $17.60 billion, a P/E ratio of -10.71, a PEG ratio of 1.44 and a beta of 0.82.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Analysts forecast that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current year.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

A number of large investors have recently modified their holdings of the company. Oarsman Capital Inc. purchased a new stake in Teva Pharmaceutical Industries during the 4th quarter worth $29,000. Marshall & Sterling Wealth Advisors Inc. purchased a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter worth about $44,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of Teva Pharmaceutical Industries in the third quarter valued at about $50,000. Ameliora Wealth Management Ltd. purchased a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter valued at about $66,000. Finally, IFP Advisors Inc lifted its position in Teva Pharmaceutical Industries by 96.1% during the 4th quarter. IFP Advisors Inc now owns 3,999 shares of the company’s stock worth $88,000 after acquiring an additional 1,960 shares in the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.